AXA/2026/1Q/Activity indicators press release: Difference between revisions
Render quote passages as blockquotes (surgical) |
PlumBot: publish from draft |
||
| Line 18: | Line 18: | ||
== 1Q26 highlights == |
== 1Q26 highlights == |
||
* '''Gross written premiums & other revenues''' +6% |
* '''Gross written premiums & other revenues''' +6% to EUR 38.0bn vs. 1Q25 <sup>p. 1</sup>. |
||
** '''Property & Casualty premiums''' +4% to EUR 21.5bn <sup>p. 1</sup> |
** '''Property & Casualty premiums''' +4% to EUR 21.5bn <sup>p. 1</sup>. |
||
*** '''Retail premiums''' +7%, with +4% from price effect and +3% from volumes <sup>p. 1</sup> |
*** '''Retail premiums''' +7%, with +4% from price effect and +3% from volumes <sup>p. 1</sup>. |
||
*** '''Commercial premiums''' +3%, with equal contributions from price effect and volumes <sup>p. 1</sup> |
*** '''Commercial premiums''' +3%, with equal contributions from price effect and volumes <sup>p. 1</sup>. |
||
** '''Life & Health premiums''' +8% to EUR 16.5bn <sup>p. 1</sup> |
** '''Life & Health premiums''' +8% to EUR 16.5bn <sup>p. 1</sup>. |
||
*** '''Life premiums''' +8% <sup>p. 1</sup> |
*** '''Life premiums''' +8% <sup>p. 1</sup>. |
||
*** '''Health premiums''' +8% <sup>p. 1</sup> |
*** '''Health premiums''' +8% <sup>p. 1</sup>. |
||
* '''Life & Health NB CSM''' +4% <sup>p. 1</sup> |
* '''Life & Health NB CSM''' +4% <sup>p. 1</sup>. |
||
* ''' |
* '''Net flows''' EUR +2.7bn <sup>p. 1</sup>. |
||
* '''Solvency II ratio''' at 211% as of March 31, 2026, -4 points vs. January 1, 2026 (post-grandfathering period) <sup>p. 1</sup> |
* '''Solvency II ratio''' at 211% as of March 31, 2026, -4 points vs. January 1, 2026 (post-grandfathering period), reflecting resilience in a volatile environment <sup>p. 1</sup>. |
||
== Outlook 3 == |
== Outlook 3 == |
||
* AXA is on track to achieve '''underlying earnings per share growth''' for 2026 at the upper end of the 6-8% plan target range <sup>p. 1</sup> |
* AXA is on track to achieve '''underlying earnings per share growth''' for 2026 at the upper end of the 6-8% plan target range <sup>p. 1</sup>. |
||
* AXA will present its new strategic plan for 2027-2029 on September 15, 2026 <sup>p. 1</sup> |
* AXA will present its new strategic plan for 2027-2029 on September 15, 2026 <sup>p. 1</sup>. |
||
<blockquote>"AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy. This performance underscores the continued robust expansion of our P&C businesses in both Retail and Commercial, with growth well balanced between pricing and volumes, while Life & Health revenues reflect the continuation of last year's strong momentum." |
<blockquote>"AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy," said Alban de Mailly Nesle, Chief Financial Officer of AXA . "This performance underscores the continued robust expansion of our P&C businesses in both Retail and Commercial, with growth well balanced between pricing and volumes, while Life & Health revenues reflect the continuation of last year's strong momentum." <sup>p. 1</sup></blockquote> |
||
<blockquote>"In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan." <sup>p. 1</sup></blockquote> |
<blockquote>"In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan." <sup>p. 1</sup></blockquote> |
||
<blockquote>"I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA." <sup>p. 1</sup></blockquote> |
<blockquote>"I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA ." <sup>p. 1</sup></blockquote> |
||
* |
* The press release was issued in Paris on May 5, 2026, at 5:45pm CET <sup>p. 1</sup>. |
||
* All footnotes for this press release are on page 7 <sup>p. 1</sup>. |
|||
== 1Q26 key highlights == |
== 1Q26 key highlights == |
||
| Line 42: | Line 43: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ AXA's gross written premiums and other revenues for 1Q25 and 1Q26. <sup>p. 2</sup> |
||
! style="text-align:left" | Key figures (EUR billion) |
! style="text-align:left" | Key figures (EUR billion) |
||
! class="col-s" style="text-align:right" | 1Q25 |
! class="col-s" style="text-align:right" | 1Q25 |
||
| Line 55: | Line 56: | ||
| style="text-align:right" | +6% |
| style="text-align:right" | +6% |
||
|- |
|- |
||
| style="text-align:left; padding-left:1.5em" | o/w Property & Casualty |
| style="text-align:left; padding-left:1.5em" | o/w Property & Casualty {{footnote|1=Natural catastrophe charges include natural catastrophe losses regardless of event size.}} |
||
| style="text-align:right" | 21.0 |
| style="text-align:right" | 21.0 |
||
| style="text-align:right" | 21.5 |
| style="text-align:right" | 21.5 |
||
| Line 61: | Line 62: | ||
| style="text-align:right" | +4% |
| style="text-align:right" | +4% |
||
|- |
|- |
||
| style="text-align:left; padding-left:1.5em" | o/w Life & Health {{footnote|1=Combined ratio is a non-GAAP financial measure, or alternative performance measure (“APM”). Please see the paragraph “Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures” in this press release for important information about APMs used by AXA.}} |
|||
| style="text-align:left; padding-left:1.5em" | o/w Life & Health |
|||
| style="text-align:right" | 15.5 |
| style="text-align:right" | 15.5 |
||
| style="text-align:right" | 16.5 |
| style="text-align:right" | 16.5 |
||
| Line 67: | Line 68: | ||
| style="text-align:right" | +8% |
| style="text-align:right" | +8% |
||
|- |
|- |
||
| style="text-align:left; padding-left:1.5em" | o/w Asset Management |
| style="text-align:left; padding-left:1.5em" | o/w Asset Management {{footnote|1=Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.}} |
||
| style="text-align:right" | 0.4 |
| style="text-align:right" | 0.4 |
||
| style="text-align:right" | n.m. |
| style="text-align:right" | n.m. |
||
| Line 77: | Line 78: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Solvency II ratio |
|+ AXA's Solvency II ratio for FY25, January 1, 2026, and 1Q26. <sup>p. 2</sup> |
||
! style="text-align:left" | Key figures ( |
! style="text-align:left" | Key figures (EUR billion) |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | January 1, 2026 |
! class="col-s" style="text-align:right" | January 1, 2026 |
||
| Line 84: | Line 85: | ||
! class="col-s" style="text-align:right" | Change vs. January 1, 2026 |
! class="col-s" style="text-align:right" | Change vs. January 1, 2026 |
||
|- |
|- |
||
| style="text-align:left" | Solvency II ratio (%) {{footnote|1=The Solvency II ratio is estimated primarily using AXA’s internal model calibrated based on an adverse 1/200 years shock. It includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026, based on the full-year dividend of Euro 2.32 per share to be paid in 2026 for FY25 and annual share buyback of Euro 1.25 billion announced on February 26, 2026. Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stock- based compensation. Dividends and share buybacks are proposed by the Board, at its discretion based on a variety of factors described in AXA’s 2025 Universal Registration Document and then submitted to AXA’s shareholders for approval. This estimate should not be considered in any way to be an indication of the actual dividend and share buyback amounts, if any, for the 2026 financial year. For further information on AXA’s internal model and Solvency II disclosures, please refer to AXA Group’s Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on AXA’s website (www.axa.com).}} |
|||
| style="text-align:left" | Solvency II ratio (%) 2 |
|||
| style="text-align:right" | 224% |
| style="text-align:right" | 224% |
||
| style="text-align:right" | 215% |
| style="text-align:right" | 215% |
||
| Line 94: | Line 95: | ||
== Activity indicators == |
== Activity indicators == |
||
* '''Total gross written premiums & other revenues''' +6% <sup>p. 2</sup> |
* '''Total gross written premiums & other revenues''' +6% <sup>p. 2</sup>. |
||
** '''Property & Casualty''' +4% |
** '''Property & Casualty''' +4%, driven by: |
||
*** '''Personal lines''' +7%, |
*** '''Personal lines''' +7%, due to higher volumes and favorable price effect <sup>p. 2</sup>. |
||
*** '''Commercial lines''' +3%, from higher volumes (notably at AXA XL Insurance) and favorable price effect |
*** '''Commercial lines''' +3%, from higher volumes (notably at AXA XL Insurance) and favorable price effect, mainly in the SME & Mid-market business in Europe and France <sup>p. 2</sup>. |
||
*** '''AXA XL Reinsurance''' -7%, reflecting discipline in softening market conditions <sup>p. 2</sup> |
*** '''AXA XL Reinsurance''' -7%, reflecting discipline in softening market conditions <sup>p. 2</sup>. |
||
** '''Life & Health''' +8% |
** '''Life & Health''' +8%, driven by: |
||
*** '''Life premiums''' +8%, |
*** '''Life premiums''' +8%, due to strong sales in Unit-Linked (+16%) and G/A (+9%) across all geographies, and Protection (+4%) from strong sales in Protection with Savings in Hong Kong and Japan <sup>p. 2</sup>. |
||
*** '''Health premiums''' +8%, |
*** '''Health premiums''' +8%, due to favorable price effects across all geographies <sup>p. 2</sup>. |
||
* '''Solvency II ratio''' was 211% as of March 31, 2026 <sup>p. 2</sup> |
* '''Solvency II ratio''' was 211% as of March 31, 2026 <sup>p. 2</sup>. |
||
* On January 1, 2026, the '''Solvency II ratio''' was 215% following the end of the grandfathering period (-10 points vs. December 31, 2025) <sup>p. 2</sup> |
* On January 1, 2026, the '''Solvency II ratio''' was 215% following the end of the grandfathering period (-10 points vs. December 31, 2025) <sup>p. 2</sup>. |
||
* The '''Solvency II ratio''' was |
* The '''Solvency II ratio''' was -4 points vs. January 1, 2026, reflecting: |
||
** A strong operating return (+7 points) <sup>p. 2</sup>. |
|||
** Less accrued dividend and annual share buyback for 1Q26 (-6 points) <sup>p. 2</sup>. |
|||
** Unfavorable financial market movements (-4 points), notably from higher inflation expectations and elevated equity and interest rate volatility <sup>p. 2</sup>. |
|||
== Property & Casualty == |
== Property & Casualty == |
||
| Line 110: | Line 114: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ P&C gross written premiums and other revenues for 1Q25 and 1Q26. <sup>p. 3</sup> |
||
! style="text-align:left" | Key figures (EUR billion) |
! style="text-align:left" | Key figures (EUR billion) |
||
! class="col-s" style="text-align:right" | 1Q25 |
! class="col-s" style="text-align:right" | 1Q25 |
||
! class="col-s" style="text-align:right" | 1Q26 |
! class="col-s" style="text-align:right" | 1Q26 |
||
! class="col-s" style="text-align:right" | Change LFL |
! class="col-s" style="text-align:right" | Change LFL |
||
! class="col-s" style="text-align:right" | 1Q26 Price effect 6 (%) |
! class="col-s" style="text-align:right" | 1Q26 Price effect 6 (in %) {{footnote|1=Price effect is calculated as a percentage of total gross written premiums of the prior year.}} |
||
|- |
|- |
||
| style="text-align:left" | Gross written premiums and other revenues |
| style="text-align:left" | Gross written premiums and other revenues |
||
| Line 143: | Line 147: | ||
</div> |
</div> |
||
* '''Gross written premiums & other revenues''' +4% to EUR 21.5bn <sup>p. 3</sup> |
* '''Gross written premiums & other revenues''' +4% to EUR 21.5bn <sup>p. 3</sup>. |
||
** '''Personal lines''' +7% to EUR 7.0bn, driven by: |
** '''Personal lines''' +7% to EUR 7.0bn, driven by: |
||
*** Europe (+7%), from favorable price effects (except UK & Ireland) and higher volumes <sup>p. 3</sup> |
*** Europe (+7%), from favorable price effects across geographies (except UK & Ireland) and higher volumes <sup>p. 3</sup>. |
||
*** France (+8%), with strong volume growth from direct business and proprietary agent networks, combined with favorable price effect <sup>p. 3</sup> |
*** France (+8%), with strong volume growth from direct business and proprietary agent networks, combined with favorable price effect <sup>p. 3</sup>. |
||
*** Asia, Africa & EME LATAM (+7%), mainly driven by higher average premiums in Türkiye and higher volumes in Mexico <sup>p. 3</sup> |
*** Asia, Africa & EME LATAM (+7%), mainly driven by higher average premiums in Türkiye and higher volumes in Mexico <sup>p. 3</sup>. |
||
** '''Commercial lines''' +3% to EUR 13.2bn, mainly from: |
** '''Commercial lines''' +3% to EUR 13.2bn, mainly from: |
||
*** AXA XL Insurance (+2%), from growth in Property and Specialty where margins remain attractive, partly offset by lower volumes in Casualty; pricing overall remains stable vs. 1Q25 <sup>p. 3</sup> |
*** AXA XL Insurance (+2%), from growth in Property and Specialty where margins remain attractive, partly offset by lower volumes in Casualty; pricing overall remains stable vs. 1Q25 <sup>p. 3</sup>. |
||
*** France (+6%), from both favorable price effect and higher volumes <sup>p. 3</sup> |
*** France (+6%), from both favorable price effect and higher volumes <sup>p. 3</sup>. |
||
*** Asia, Africa & EME-LATAM (+10%), mainly driven by higher average premiums in Türkiye <sup>p. 3</sup> |
*** Asia, Africa & EME-LATAM (+10%), mainly driven by higher average premiums in Türkiye <sup>p. 3</sup>. |
||
** '''AXA XL Reinsurance''' -7% to EUR 1.2bn, reflecting lower volumes consistent with focus on profitability in a softer market, with pricing down -4% <sup>p. 3</sup> |
** '''AXA XL Reinsurance''' -7% to EUR 1.2bn, reflecting lower volumes consistent with focus on maintaining profitability in a softer market environment, with pricing down -4% <sup>p. 3</sup>. |
||
* '''Group natural catastrophe experience''' in 1Q26 was slightly below the prorated annual budget <sup>p. 3</sup> |
* '''Group natural catastrophe experience''' in 1Q26 was slightly below the prorated annual budget <sup>p. 3</sup>. |
||
* The annual '''natural catastrophe budget''' of approximately 4.5 points of combined ratio is maintained <sup>p. 3</sup> |
* The annual '''natural catastrophe budget''' of approximately 4.5 points of combined ratio is maintained <sup>p. 3</sup>. |
||
== Life & Health == |
== Life & Health == |
||
| Line 160: | Line 164: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Life & |
|+ Life & Health key figures for 1Q25 and 1Q26. <sup>p. 4</sup> |
||
! style="text-align:left" | Key figures (EUR billion) |
! style="text-align:left" | Key figures (EUR billion) |
||
! class="col-s" style="text-align:right" | 1Q25 |
! class="col-s" style="text-align:right" | 1Q25 |
||
| Line 217: | Line 221: | ||
</div> |
</div> |
||
* 1Q25 PVEP, NB CSM, NBV, and NBV margin have been updated based on FY25 financial and actuarial assumptions for comparability <sup>p. 4</sup> |
* 1Q25 PVEP, NB CSM, NBV, and NBV margin have been updated based on FY25 financial and actuarial assumptions for comparability, reflecting their contribution to FY25 PVEP, NB CSM, NBV, and NBV margin <sup>p. 4</sup>. |
||
* |
* All year-on-year changes are on a comparable basis vs. the updated 1Q25 figures <sup>p. 4</sup>. |
||
* '''Gross written premiums & other revenues''' +8% to EUR 16.5bn <sup>p. 4</sup>. |
|||
** '''Life premiums''' +8% to EUR 10.5bn, driven by: |
|||
*** Unit-Linked (+16%), from continued positive sales momentum across geographies <sup>p. 4</sup> |
|||
*** Unit-Linked (+16%), from continued positive sales momentum across geographies <sup>p. 4</sup>. |
|||
*** G/A Savings (+9%), mainly from successful commercial campaigns in Spain, strong single-premium sales in Japan, good performance of G/A capital-light products in Italy, and positive momentum in Individual Savings in Switzerland <sup>p. 4</sup> |
|||
*** |
*** G/A Savings (+9%), mainly from successful commercial campaigns in Spain, strong single-premium sales in Japan, good performance of G/A capital-light products in Italy, and positive momentum in Individual Savings in Switzerland <sup>p. 4</sup>. |
||
*** Protection (+4%), primarily from continued success of Protection with G/A savings in Hong-Kong and Protection with Unit-Linked in Japan, as well as Individual Protection with Savings in Switzerland <sup>p. 4</sup>. |
|||
** '''Health premiums''' +8% to EUR 5.9bn, driven by favorable price effects across all geographies <sup>p. 4</sup> |
|||
* ''' |
** '''Health premiums''' +8% to EUR 5.9bn, driven by favorable price effects across all geographies <sup>p. 4</sup>. |
||
* '''PVEP''' +8% to EUR 13.8bn, driven by: |
|||
** Life (+10%), reflecting strong sales across geographies in both Savings (+14%) and Protection (+6%), partly offset by lower Group Life sales in Switzerland <sup>p. 4</sup> |
|||
** |
** Life (+10%), reflecting strong sales across geographies in both Savings (+14%) and Protection (+6%), partly offset by lower Group Life sales in Switzerland <sup>p. 4</sup>. |
||
* |
** Health (+4%), mainly due to higher Group business volumes in France, partly offset by Japan <sup>p. 4</sup>. |
||
* ''' |
* '''NB CSM (pre-tax)''' +4% to EUR 0.6bn, driven by strong Savings and Protection sales across most geographies, partly offset by unfavorable mix, including lower Group Life sales in Switzerland and Health sales in Japan <sup>p. 4</sup>. |
||
* '''NBV (post-tax)''' +1% to EUR 0.6bn, as NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China <sup>p. 4</sup>. |
|||
* '''NBV margin''' -0.3 points to 4.4% <sup>p. 4</sup> |
|||
* ''' |
* '''NBV margin''' -0.3 points to 4.4% <sup>p. 4</sup>. |
||
* '''Net flows''' EUR +2.7bn (vs. EUR +2.5bn in 1Q25), driven by: |
|||
** Protection (EUR +1.8bn), mainly in Hong Kong and Switzerland in Individual Life, and in Japan in Protection with Unit-Linked product <sup>p. 4</sup> |
|||
** |
** Protection (EUR +1.8bn), mainly in Hong Kong and Switzerland in Individual Life, and in Japan in Protection with Unit-Linked product <sup>p. 4</sup>. |
||
** |
** Unit-Linked (EUR +0.7bn), primarily in France <sup>p. 4</sup>. |
||
** G/A Savings (EUR -0.8bn), reflecting inflows in capital-light G/A savings (EUR +0.7bn), more than offset by outflows in traditional G/A Savings (EUR -1.5bn) <sup>p. 4</sup>. |
|||
** Health (EUR +1.0bn), mostly from Germany, France and Japan <sup>p. 4</sup> |
|||
** Health (EUR +1.0bn), mostly from Germany, France and Japan <sup>p. 4</sup>. |
|||
== Ratings == |
== Ratings == |
||
| Line 240: | Line 245: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" |
{| class="wikitable" |
||
|+ Insurer financial strength and AXA's credit ratings. <sup>p. 5</sup> |
|+ Insurer financial strength and AXA's credit ratings by agency. <sup>p. 5</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! style="text-align:center" | |
! style="text-align:center" | |
||
! colspan="3" style="text-align:center" | Insurer financial strength ratings |
! colspan="3" style="text-align:center" | Insurer financial strength ratings |
||
! colspan="2" style="text-align:center" | AXA's credit ratings |
! colspan="2" style="text-align:center" | AXA's credit ratings {{footnote|1=Restricted Tier 1: “A-” by Standard & Poor’s and “A3(hyb)” by Moody’s. Tier 2: “A” by Standard & Poor’s and “A1(hyb)” by Moody’s.}} |
||
|- |
|- |
||
! style="text-align:left" | Agency |
! style="text-align:left" | Agency |
||
| Line 281: | Line 286: | ||
== Glossary == |
== Glossary == |
||
* '''Capital-light G/A products''' encompass all products with no guarantees, with guarantees at maturity only, or with guarantees equal to or lower than 0% <sup>p. 5</sup> |
* '''Capital-light G/A products''' encompass all products with no guarantees, with guarantees at maturity only, or with guarantees equal to or lower than 0% <sup>p. 5</sup>. |
||
* '''Contractual service margin ('CSM')''' is a component of the carrying amount of the asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders <sup>p. 5</sup> |
* '''Contractual service margin ('CSM')''' is a component of the carrying amount of the asset or liability for a group of insurance contracts, representing the unearned profit to be recognized as services are provided to policyholders <sup>p. 5</sup>. |
||
* '''Gross written premiums and other revenues''' are insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business) <sup>p. 5</sup> |
* '''Gross written premiums and other revenues''' are insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business) <sup>p. 5</sup>. |
||
* '''Other Revenues''' represent premiums and fees collected on activities other than insurance (i.e., banking, services, and asset management activities) <sup>p. 5</sup> |
* '''Other Revenues''' represent premiums and fees collected on activities other than insurance (i.e., banking, services, and asset management activities) <sup>p. 5</sup>. |
||
* '''New business contractual service margin ('NB CSM')''' is a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided <sup>p. 5</sup> |
* '''New business contractual service margin ('NB CSM')''' is a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided <sup>p. 5</sup>. |
||
* '''New business value ('NBV')''' is the value of newly issued contracts during the current year, consisting of |
* '''New business value ('NBV')''' is the value of newly issued contracts during the current year, consisting of: |
||
** The NB CSM <sup>p. 5</sup>. |
|||
* '''New business value margin ('NBV Margin')''' is the ratio of (i) NBV to (ii) PVEP <sup>p. 5</sup> |
|||
** The present value of future profits of Short-Term Business newly issued contracts during the period, carried by Life entities, considering expected renewals <sup>p. 5</sup>. |
|||
* '''Present value of expected premiums ('PVEP')''' is the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term, discounted at the reference interest rate and representing Group share <sup>p. 5</sup> |
|||
** The present value of future profits of pure investment contracts accounted for under IFRS 9 <sup>p. 5</sup>. |
|||
** Net of the cost of reinsurance, taxes, and minority interests <sup>p. 5</sup>. |
|||
* '''New business value margin ('NBV Margin')''' is the ratio of NBV to PVEP <sup>p. 5</sup>. |
|||
* '''Present value of expected premiums ('PVEP')''' is the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term, discounted at the reference interest rate and representing the Group share <sup>p. 5</sup>. |
|||
* '''AA''': Senior Debt Rating |
|||
* '''AM''': AM Best |
* '''AM''': AM Best |
||
* ''' |
* '''BNP''': Banque Nationale de Paris |
||
* '''CLP''': Credit and Lifestyle Protection |
* '''CLP''': Credit and Lifestyle Protection |
||
* '''CSM''': Contractual Service Margin |
* '''CSM''': Contractual Service Margin |
||
* '''EME LATAM''': Emerging Markets Europe Latin America |
|||
* '''DJSI''': Dow Jones Sustainability Index |
|||
* '''DPF''': Discretionary Participation Features |
|||
* '''EME''': Emerging Markets Europe |
* '''EME''': Emerging Markets Europe |
||
* '''ESMA''': European Securities and Markets Authority |
|||
* '''GAAP''': Generally Accepted Accounting Principles |
|||
* '''GWP''': Gross Written Premiums |
|||
* '''IFRS''': International Financial Reporting Standards |
* '''IFRS''': International Financial Reporting Standards |
||
* '''II''': Solvency II |
|||
* '''LATAM''': Latin America |
|||
* '''LFL''': Like-for-Like |
* '''LFL''': Like-for-Like |
||
* '''NB CSM''': New Business Contractual Service Margin |
* '''NB CSM''': New Business Contractual Service Margin |
||
* '''NBV''': New Business Value |
* '''NBV''': New Business Value |
||
* '''OTC QX''': Over The Counter QX |
|||
* '''PVEP''': Present Value of Expected Premiums |
* '''PVEP''': Present Value of Expected Premiums |
||
* '''SFCR''': Solvency and Financial Condition Report |
|||
* '''SME''': Small and Medium-sized Enterprises |
* '''SME''': Small and Medium-sized Enterprises |
||
* ''' |
* '''UK''': United Kingdom |
||
* '''UEPS''': Underlying Earnings Per Share |
|||
* '''UN''': United Nations |
|||
* '''UNEP FI''': United Nations Environment Programme's Finance Initiative |
|||
== Scope == |
== Scope == |
||
* '''France''' includes insurance activities, banking activities, and holding <sup>p. 6</sup> |
* '''France''' includes insurance activities, banking activities, and holding <sup>p. 6</sup>. |
||
* '''Europe''' includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and |
* '''Europe''' includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxembourg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holding), Italy (insurance activities), Prima (insurance activities), AXA Health International (insurance activities), and AXA Life Europe (insurance activities) <sup>p. 6</sup>. |
||
* '''AXA XL''' includes insurance and reinsurance activities and holding <sup>p. 6</sup> |
* '''AXA XL''' includes insurance and reinsurance activities and holding <sup>p. 6</sup>. |
||
* '''Asia, Africa & EME-LATAM''' includes: |
* '''Asia, Africa & EME-LATAM''' includes: |
||
** Asia: Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, Indonesia L&S (excluding bancassurance entity), China P&C, South Korea, and Asia Holdings (fully consolidated); China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S (bancassurance entity) (consolidated under equity method, contributing only to NBV, PVEP, underlying earnings, and net income) <sup>p. 6</sup> |
** '''Asia''': Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, Indonesia L&S (excluding the bancassurance entity), China P&C, South Korea, and Asia Holdings (fully consolidated); China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S (the bancassurance entity) (consolidated under the equity method, contributing only to NBV, PVEP, underlying earnings, and net income) <sup>p. 6</sup>. |
||
** Africa: Egypt (insurance activities and holding), Morocco (insurance activities and holding), and Nigeria (insurance activities and holding) (fully consolidated) <sup>p. 6</sup> |
** '''Africa''': Egypt (insurance activities and holding), Morocco (insurance activities and holding), and Nigeria (insurance activities and holding) (fully consolidated) <sup>p. 6</sup>. |
||
** EME-LATAM: Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding) (fully consolidated); Russia (Reso) (insurance activities) (consolidated under equity method, contributing only to net income) <sup>p. 6</sup> |
** '''EME-LATAM''': Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding) (fully consolidated); Russia (Reso) (insurance activities) (consolidated under the equity method, contributing only to net income) <sup>p. 6</sup>. |
||
** AXA Mediterranean Holdings <sup>p. 6</sup> |
** '''AXA Mediterranean Holdings''' <sup>p. 6</sup>. |
||
* '''Transversal & Other''' includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA (including Group's internal reinsurance activity), and other Central Holdings <sup>p. 6</sup> |
* '''Transversal & Other''' includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA (including the Group's internal reinsurance activity), and other Central Holdings <sup>p. 6</sup>. |
||
* The disposal of '''AXA Investment Managers''' to BNP Paribas was completed on July 1, 2025 <sup>p. 6</sup> |
* The disposal of '''AXA Investment Managers''' to BNP Paribas was completed on July 1, 2025 <sup>p. 6</sup>. |
||
== Exchange rates == |
== Exchange rates == |
||
| Line 328: | Line 331: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Exchange rates for major currencies in FY25, 1Q25, and 1Q26. <sup>p. 6</sup> |
||
! style="text-align:left" | For 1 Euro |
|||
! colspan="2" style="text-align:center" | End of Period Exchange rate |
|||
! colspan="2" style="text-align:center" | Average Exchange rate |
|||
|- |
|||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 373: | Line 372: | ||
== Notes == |
== Notes == |
||
* Changes in |
* '''Changes in gross written premiums & other revenues, new business value (NBV), present value of expected premiums (PVEP), and new business value margin (NBV Margin)''' are on a comparable basis (constant forex, scope, and methodology) unless otherwise indicated <sup>p. 7</sup>. |
||
* |
* These and other terms are defined in the glossary section of the press release <sup>p. 7</sup>. |
||
* The '''Solvency II ratio''' |
* The '''Solvency II ratio''' is estimated using AXA's internal model, calibrated based on an adverse 1/200 years shock <sup>p. 7</sup>. |
||
- |
|||
* Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stock-based compensation <sup>p. 7</sup> |
|||
* Dividends and share buybacks are proposed by the Board and submitted to shareholders for approval <sup>p. 7</sup> |
|||
* The estimate of the Solvency II ratio should not be considered an indication of actual dividend and share buyback amounts for the 2026 financial year <sup>p. 7</sup> |
|||
* Information on AXA's internal model and Solvency II disclosures is available in AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, on axa.com <sup>p. 7</sup> |
|||
* '''Expected underlying earnings per share ('UEPS') growth''' for 2026 is a forward-looking statement providing one-off guidance for the last year of the current strategic plan <sup>p. 7</sup> |
|||
* '''Commercial lines''' refers to P&C Commercial lines excluding AXA XL Reinsurance <sup>p. 7</sup> |
|||
* '''Price effect''' is calculated as a percentage of total gross written premiums of the prior year <sup>p. 7</sup> |
|||
* '''G/A''' refers to General account <sup>p. 7</sup> |
|||
* Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, after which they ceased to qualify as capital under Solvency II <sup>p. 7</sup> |
|||
* '''Natural catastrophe charges''' include natural catastrophe losses regardless of event size <sup>p. 7</sup> |
|||
* '''Combined ratio''' is a non-GAAP financial measure <sup>p. 7</sup> |
|||
* '''Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin''' include Health business predominantly written in Life entities <sup>p. 7</sup> |
|||
* Restricted Tier 1 ratings are 'A' by Standard & Poor's and 'A3 (hyb)' by Moody's <sup>p. 7</sup> |
|||
* Tier 2 ratings are 'A' by Standard & Poor's and 'A (hyb)' by Moody's <sup>p. 7</sup> |
|||
* AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025 <sup>p. 7</sup> |
|||
* All comments and changes for activity indicators are on a comparable basis (constant forex, scope, and methodology) <sup>p. 7</sup> |
|||
* Actuarial and financial assumptions for NBV and PVEP are updated semi-annually at half year and full year <sup>p. 7</sup> |
|||
* Financial figures and information in this press release have not been audited or subject to limited review by AXA's statutory auditors <sup>p. 7</sup> |
|||
== About the AXA Group == |
|||
* The '''AXA Group''' is a worldwide leader in insurance with 156,000 employees serving over 92 million clients in 52 countries <sup>p. 8</sup> |
|||
* In 2025, '''revenues''' amounted to EUR 115.5bn and '''underlying earnings''' to EUR 8.4bn <sup>p. 8</sup> |
|||
* The '''AXA ordinary share''' is listed on compartment A of Euronext Paris under ticker symbol CS (ISN FR 0000120628 - Bloomberg: CS FP - Reuters: AXAF.PA) <sup>p. 8</sup> |
|||
* AXA's '''American Depository Share''' is quoted on the OTC QX platform under ticker symbol AXAHY <sup>p. 8</sup> |
|||
* The '''AXA Group''' is included in main international SRI indexes, such as Dow Jones Sustainability Index (DJSI) and FTSE4GOOD <sup>p. 8</sup> |
|||
* AXA is a founding member of the UN Environment Programme's Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment <sup>p. 8</sup> |
|||
* This press release and regulated information are available on the AXA Group website (axa.com) <sup>p. 8</sup> |
|||
* Certain statements in this press release are forward-looking statements, subject to known and unknown risks and uncertainties, and should not be unduly relied upon <sup>p. 8</sup> |
|||
* AXA specifically disclaims any obligation to publicly update or revise forward-looking statements, except as required by law <sup>p. 8</sup> |
|||
* This press release refers to certain non-GAAP financial measures (APMs) used by Management for analyzing operating trends, financial performance, and position <sup>p. 8</sup> |
|||
* Non-GAAP financial measures generally have no standardized meaning and may not be comparable to similarly labeled measures used by other companies <sup>p. 8</sup> |
|||
* Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Group's consolidated financial statements <sup>p. 8</sup> |
|||
* '''Underlying earnings''', '''UEPS''', '''underlying return on equity''', '''combined ratio''', and '''debt gearing''' are APMs as defined in ESMA's guidelines and the AMF's related position statement <sup>p. 8</sup> |
|||
* A reconciliation of APMs to financial statements is provided in the 2025 Universal Registration Document <sup>p. 8</sup> |
|||
* Investor Relations contact: +33.1.40.75.48.42, investor.relations@axa.com <sup>p. 8</sup> |
|||
* Individual Shareholder Relations contact: +33.1.40.75.48.43 <sup>p. 8</sup> |
|||
* Media Relations contact: +33.1.40.75.46.74, ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com <sup>p. 8</sup> |
|||
* Corporate Responsibility strategy information: axa.com/en/about-us/strategy-commitments <sup>p. 8</sup> |
|||
* SRI ratings information: axa.com/en/investor/sri-ratings-ethical-indexes <sup>p. 8</sup> |
|||
== Appendix 1: Earnings == |
|||
* '''APPENDIX 1''': Gross Written Premiums & Other Revenues by Geography and Business Line <sup>p. 9</sup> |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Gross written premiums and other revenues by segment for 1Q25 and 1Q26. <sup>p. 9</sup> |
||
! style="text-align:left" | EUR million |
|||
! colspan="5" style="text-align:center" | GWP & Other Revenues |
|||
! colspan="2" style="text-align:center" | P&C |
|||
! colspan="2" style="text-align:center" | Life & Health |
|||
|- |
|||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
! class="col-s" style="text-align:right" | 1Q25 Published |
! class="col-s" style="text-align:right" | 1Q25 Published |
||
| Line 440: | Line 391: | ||
! class="col-s" style="text-align:right" | Change LFL |
! class="col-s" style="text-align:right" | Change LFL |
||
|- |
|- |
||
| style="text-align:left" | France |
| style="text-align:left" | France |
||
| style="text-align:right" | 8,440 |
| style="text-align:right" | 8,440 |
||
| style="text-align:right" | 7,923 |
| style="text-align:right" | 7,923 |
||
| Line 451: | Line 402: | ||
| style="text-align:right" | +4% |
| style="text-align:right" | +4% |
||
|- |
|- |
||
| style="text-align:left" | Europe |
| style="text-align:left" | Europe |
||
| style="text-align:right" | 15,289 |
| style="text-align:right" | 15,289 |
||
| style="text-align:right" | 15,608 |
| style="text-align:right" | 15,608 |
||
| Line 484: | Line 435: | ||
| style="text-align:right" | +13% |
| style="text-align:right" | +13% |
||
|- |
|- |
||
| style="text-align:left" | Transversal |
| style="text-align:left" | Transversal |
||
| style="text-align:right" | 525 |
| style="text-align:right" | 525 |
||
| style="text-align:right" | 723 |
| style="text-align:right" | 723 |
||
| Line 506: | Line 457: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left; font-weight:bold" | Total |
| style="text-align:left; font-weight:bold" | Total |
||
| style="text-align:right; font-weight:bold" | 36,967 |
| style="text-align:right; font-weight:bold" | 36,967 |
||
| style="text-align:right; font-weight:bold" | 36,967 |
| style="text-align:right; font-weight:bold" | 36,967 |
||
| Line 518: | Line 469: | ||
|} |
|} |
||
</div> |
</div> |
||
* '''Banking revenues''' were EUR 26m in 1Q26 and EUR 25m in 1Q25 <sup>p. 9</sup>. |
|||
* '''Portfolio of lifestyle and income protection (CLP) premiums''' were reallocated from France to Transversal <sup>p. 9</sup>. |
|||
** '''CLP premiums''' were EUR 198m in 1Q25, with EUR 68m in P&C and EUR 130m in Life & Health <sup>p. 9</sup>. |
|||
** '''CLP premiums''' were EUR 201m in 1Q26, with EUR 68m in P&C and EUR 132m in Life & Health <sup>p. 9</sup>. |
|||
* '''International protection and health premiums''' previously reported under AXA France are now reported under AXA Health International, which is part of Europe <sup>p. 9</sup>. |
|||
** '''International protection and health premiums''' were EUR 319m in 1Q25, with EUR 104m in Life and EUR 215m in Health <sup>p. 9</sup>. |
|||
** '''International protection and health premiums''' were EUR 336m in 1Q26, with EUR 103m in Life and EUR 233m in Health <sup>p. 9</sup>. |
|||
* '''APPENDIX 1''': Earnings <sup>p. 10</sup>. |
|||
* '''APPENDIX 2''': Property & Casualty - Gross Written Premiums & Other Revenues by Business Line and Discount Rates <sup>p. 10</sup>. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ P&C |
|+ P&C gross written premiums and other revenues by segment for 1Q26. <sup>p. 10</sup> |
||
! style="text-align:left" | EUR million |
|||
! colspan="2" style="text-align:center" | Commercial lines |
|||
! colspan="5" style="text-align:center" | Personal lines |
|||
! colspan="2" style="text-align:center" | AXA XL Reinsurance |
|||
! colspan="2" style="text-align:center" | Total P&C |
|||
! style="text-align:center" | |
|||
|- |
|||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
! class="col-s" style="text-align:right" | Total Commercial |
! class="col-s" style="text-align:right" | Total Commercial |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | Personal Motor |
! class="col-s" style="text-align:right" | Personal Motor |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | Personal Non-Motor |
! class="col-s" style="text-align:right" | Personal Non-Motor |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | Total Personal |
! class="col-s" style="text-align:right" | Total Personal |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | Total Reinsurance |
! class="col-s" style="text-align:right" | Total Reinsurance |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | 1Q26 |
! class="col-s" style="text-align:right" | 1Q26 |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | France |
| style="text-align:left" | France |
||
| Line 639: | Line 573: | ||
</div> |
</div> |
||
'''Interest rates (5Y) for the discounting of P&C claims reserves''' |
|||
* '''Changes''' are on a comparable basis (constant forex, scope, and methodology) <sup>p. 10</sup>. |
|||
=== Interest rates (5Y) for the discounting of P&C claims reserves === |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Interest rates (5Y) for discounting P&C claims reserves. <sup>p. 10</sup> |
|+ Interest rates (5Y) for discounting P&C claims reserves in FY25 and 1Q26. <sup>p. 10</sup> |
||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
! class="col-s" style="text-align:right" | FY25 i |
! class="col-s" style="text-align:right" | FY25 i |
||
| Line 675: | Line 607: | ||
|} |
|} |
||
</div> |
</div> |
||
* '''APPENDIX 3''': Underlying Earnings by Geography and by Business Line <sup>p. 11</sup>. |
|||
* '''APPENDIX 3''': Property & Casualty - Price Effect by Business Line <sup>p. 11</sup>. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ P&C |
|+ Interest rates (5Y) for discounting P&C claims reserves by line of business. <sup>p. 11</sup> |
||
! style="text-align:left" | 1Q26 (%) |
! style="text-align:left" | 1Q26 (in %) |
||
! class="col-s" style="text-align:right" | Commercial lines |
! class="col-s" style="text-align:right" | Commercial lines |
||
! class="col-s" style="text-align:right" | Personal lines |
! class="col-s" style="text-align:right" | Personal lines |
||
| Line 727: | Line 656: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | AXA XL |
| style="text-align:left" | AXA XL |
||
| style="text-align:right" | -0.2% |
| style="text-align:right" | -0.2% |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| Line 743: | Line 672: | ||
|} |
|} |
||
</div> |
</div> |
||
* '''APPENDIX 4''': Property & Casualty - Revenue Contribution & Growth by Business Line <sup>p. 12</sup>. |
|||
* '''APPENDIX 4''': Life & Health - Gross Written Premiums & Other Revenues and Growth by Business Line <sup>p. 12</sup>. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ P&C gross written premiums and other revenues by segment for 1Q26. <sup>p. 12</sup> |
||
! style="text-align:left" | EUR million |
|||
! colspan="2" style="text-align:center" | Total i |
|||
! colspan="2" style="text-align:center" | Protection |
|||
! colspan="2" style="text-align:center" | G/A Savings |
|||
! colspan="2" style="text-align:center" | Unit-Linked |
|||
! colspan="2" style="text-align:center" | Health |
|||
|- |
|||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
! class="col-s" style="text-align:right" | 1Q26 |
! class="col-s" style="text-align:right" | 1Q26 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | 1Q26 |
! class="col-s" style="text-align:right" | 1Q26 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | 1Q26 |
! class="col-s" style="text-align:right" | 1Q26 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | 1Q26 |
! class="col-s" style="text-align:right" | 1Q26 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | 1Q26 |
! class="col-s" style="text-align:right" | 1Q26 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | France |
| style="text-align:left" | France |
||
| Line 841: | Line 760: | ||
| style="text-align:right; font-weight:bold" | +8% |
| style="text-align:right; font-weight:bold" | +8% |
||
|- |
|- |
||
| style="text-align:left; padding-left:1.5em" | o/w short-term |
| style="text-align:left; padding-left:1.5em" | o/w short-term |
||
| style="text-align:right" | 5,436 |
| style="text-align:right" | 5,436 |
||
| style="text-align:right" | +6% |
| style="text-align:right" | +6% |
||
| Line 854: | Line 773: | ||
|} |
|} |
||
</div> |
</div> |
||
* '''APPENDIX 4''': Property & Casualty - Revenue Contribution & Growth by Business Line <sup>p. 13</sup>. |
|||
* '''APPENDIX 5''': Life & Health - Updated PVEP, NB CSM, NBV, and NBV margin <sup>p. 13</sup>. |
|||
* '''PVEP, NB CSM, NBV, and NBV margin''' for 1Q25, 1H25, and 9M25 have been updated based on FY25 actuarial and financial assumptions <sup>p. 13</sup>. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Life & Health gross written premiums and other revenues by segment for 1Q26. <sup>p. 13</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | — |
||
! colspan="4" style="text-align:center" | Life |
! colspan="4" style="text-align:center" | Life |
||
! colspan="4" style="text-align:center" | Healthⁱ |
! colspan="4" style="text-align:center" | Healthⁱ |
||
! colspan="4" style="text-align:center" | Totalⁱ |
! colspan="4" style="text-align:center" | Totalⁱ |
||
|- |
|- |
||
| style="text-align:left" | France |
|||
! class="col-s" style="text-align:right" | PVEP |
|||
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
|||
! class="col-s" style="text-align:right" | NBV (post-tax) |
|||
! class="col-s" style="text-align:right" | NBV margin (%) |
|||
! class="col-s" style="text-align:right" | PVEP |
|||
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
|||
! class="col-s" style="text-align:right" | NBV (post-tax) |
|||
! class="col-s" style="text-align:right" | NBV margin (%) |
|||
! class="col-s" style="text-align:right" | PVEP |
|||
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
|||
! class="col-s" style="text-align:right" | NBV (post-tax) |
|||
! class="col-s" style="text-align:right" | NBV margin (%) |
|||
|- |
|||
| style="text-align:left" | France ii,iii |
|||
| style="text-align:right" | 3,026 |
| style="text-align:right" | 3,026 |
||
| style="text-align:right" | 94 |
| style="text-align:right" | 94 |
||
| Line 895: | Line 796: | ||
| style="text-align:right" | 3.2% |
| style="text-align:right" | 3.2% |
||
|- |
|- |
||
| style="text-align:left" | Europe |
| style="text-align:left" | Europe |
||
| style="text-align:right" | 2,982 |
| style="text-align:right" | 2,982 |
||
| style="text-align:right" | 183 |
| style="text-align:right" | 183 |
||
| Line 923: | Line 824: | ||
| style="text-align:right" | 6.6% |
| style="text-align:right" | 6.6% |
||
|- |
|- |
||
| style="text-align:left" | Transversal |
| style="text-align:left" | Transversal |
||
| style="text-align:right" | 63 |
| style="text-align:right" | 63 |
||
| style="text-align:right" | 5 |
| style="text-align:right" | 5 |
||
| Line 955: | Line 856: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Life & Health gross written premiums and other revenues by segment for 1Q26. <sup>p. 13</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | — |
||
! colspan="4" style="text-align:center" | Life |
! colspan="4" style="text-align:center" | Life |
||
! colspan="4" style="text-align:center" | Healthᶦ |
! colspan="4" style="text-align:center" | Healthᶦ |
||
! colspan="4" style="text-align:center" | Totalᶦ |
! colspan="4" style="text-align:center" | Totalᶦ |
||
|- |
|- |
||
| style="text-align:left" | France |
|||
! class="col-s" style="text-align:right" | PVEP |
|||
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
|||
! class="col-s" style="text-align:right" | NBV (post-tax) |
|||
! class="col-s" style="text-align:right" | NBV margin (%) |
|||
! class="col-s" style="text-align:right" | PVEP |
|||
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
|||
! class="col-s" style="text-align:right" | NBV (post-tax) |
|||
! class="col-s" style="text-align:right" | NBV margin (%) |
|||
! class="col-s" style="text-align:right" | PVEP |
|||
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
|||
! class="col-s" style="text-align:right" | NBV (post-tax) |
|||
! class="col-s" style="text-align:right" | NBV margin (%) |
|||
|- |
|||
| style="text-align:left" | France ii,iii |
|||
| style="text-align:right" | 6,969 |
| style="text-align:right" | 6,969 |
||
| style="text-align:right" | 204 |
| style="text-align:right" | 204 |
||
| Line 989: | Line 876: | ||
| style="text-align:right" | 3.2% |
| style="text-align:right" | 3.2% |
||
|- |
|- |
||
| style="text-align:left" | Europe |
| style="text-align:left" | Europe |
||
| style="text-align:right" | 5,585 |
| style="text-align:right" | 5,585 |
||
| style="text-align:right" | 328 |
| style="text-align:right" | 328 |
||
| Line 1,017: | Line 904: | ||
| style="text-align:right" | 6.8% |
| style="text-align:right" | 6.8% |
||
|- |
|- |
||
| style="text-align:left" | Transversal |
| style="text-align:left" | Transversal |
||
| style="text-align:right" | 153 |
| style="text-align:right" | 153 |
||
| style="text-align:right" | 12 |
| style="text-align:right" | 12 |
||
| Line 1,049: | Line 936: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ PVEP, NB CSM, NBV, and NBV margin by segment for 1Q26. <sup>p. 13</sup> |
||
! style="text-align:left" | EUR million |
|||
! colspan="4" style="text-align:center" | Life |
|||
! colspan="4" style="text-align:center" | Health i |
|||
! colspan="4" style="text-align:center" | Total i |
|||
|- |
|||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
! class="col-s" style="text-align:right" | PVEP |
! class="col-s" style="text-align:right" | PVEP |
||
| Line 1,069: | Line 951: | ||
! class="col-s" style="text-align:right" | NBV margin (%) |
! class="col-s" style="text-align:right" | NBV margin (%) |
||
|- |
|- |
||
| style="text-align:left" | France |
| style="text-align:left" | France |
||
| style="text-align:right" | 9,911 |
| style="text-align:right" | 9,911 |
||
| style="text-align:right" | 277 |
| style="text-align:right" | 277 |
||
| Line 1,083: | Line 965: | ||
| style="text-align:right" | 3.1% |
| style="text-align:right" | 3.1% |
||
|- |
|- |
||
| style="text-align:left" | Europe |
| style="text-align:left" | Europe |
||
| style="text-align:right" | 7,900 |
| style="text-align:right" | 7,900 |
||
| style="text-align:right" | 450 |
| style="text-align:right" | 450 |
||
| Line 1,111: | Line 993: | ||
| style="text-align:right" | 7.0% |
| style="text-align:right" | 7.0% |
||
|- |
|- |
||
| style="text-align:left" | Transversal |
| style="text-align:left" | Transversal |
||
| style="text-align:right" | 230 |
| style="text-align:right" | 230 |
||
| style="text-align:right" | 18 |
| style="text-align:right" | 18 |
||
| Line 1,143: | Line 1,025: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ 1Q25 updated figures for |
|+ 1Q25 updated NB CSM to NBV figures for Life and Health. <sup>p. 13</sup> |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | Life |
! class="col-s" style="text-align:right" | Life |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Healthⁱ |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Totalⁱ |
||
|- |
|- |
||
| style="text-align:left" | NB CSM (pre-tax) |
| style="text-align:left" | NB CSM (pre-tax) |
||
| Line 1,173: | Line 1,055: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ 1H25 updated figures for |
|+ 1H25 updated NB CSM to NBV figures for Life and Health. <sup>p. 13</sup> |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | Life |
! class="col-s" style="text-align:right" | Life |
||
| Line 1,203: | Line 1,085: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ 9M25 updated figures for |
|+ 9M25 updated NB CSM to NBV figures for Life and Health. <sup>p. 13</sup> |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | Life |
! class="col-s" style="text-align:right" | Life |
||
| Line 1,230: | Line 1,112: | ||
|} |
|} |
||
</div> |
</div> |
||
* '''APPENDIX 9''': Other <sup>p. 14</sup>. |
|||
* '''APPENDIX 6''': PVEP, NB CSM, NBV, and NBV margin <sup>p. 14</sup>. |
|||
* '''Change vs. 1Q25''' updated figures are based on FY25 financial and actuarial assumptions <sup>p. 14</sup>. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ PVEP, NB CSM, NBV, and NBV margin by segment for 1Q26. <sup>p. 14</sup> |
||
! style="text-align:left" | EUR million |
|||
! colspan="8" style="text-align:center" | Life New Business Metrics 1Q26 |
|||
! colspan="8" style="text-align:center" | Healthⁱ New Business Metrics 1Q26 |
|||
! colspan="8" style="text-align:center" | Totalⁱ New Business Metrics 1Q26 |
|||
|- |
|||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
! class="col-s" style="text-align:right" | PVEP |
! class="col-s" style="text-align:right" | PVEP |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | NBV (post-tax) |
! class="col-s" style="text-align:right" | NBV (post-tax) |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | NBV margin (%) |
! class="col-s" style="text-align:right" | NBV margin (%) |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | PVEP |
! class="col-s" style="text-align:right" | PVEP |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | NBV (post-tax) |
! class="col-s" style="text-align:right" | NBV (post-tax) |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | NBV margin (%) |
! class="col-s" style="text-align:right" | NBV margin (%) |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | PVEP |
! class="col-s" style="text-align:right" | PVEP |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
! class="col-s" style="text-align:right" | NB CSM (pre-tax) |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | NBV (post-tax) |
! class="col-s" style="text-align:right" | NBV (post-tax) |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
! class="col-s" style="text-align:right" | NBV margin (%) |
! class="col-s" style="text-align:right" | NBV margin (%) |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | France |
||
| style="text-align:right" | 3,348 |
| style="text-align:right" | 3,348 |
||
| style="text-align:right" | +11% |
| style="text-align:right" | +11% |
||
| Line 1,295: | Line 1,168: | ||
| style="text-align:right" | -0.1 pt |
| style="text-align:right" | -0.1 pt |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Europe |
||
| style="text-align:right" | 3,287 |
| style="text-align:right" | 3,287 |
||
| style="text-align:right" | +8% |
| style="text-align:right" | +8% |
||
| Line 1,347: | Line 1,220: | ||
| style="text-align:right" | -0.5 pt |
| style="text-align:right" | -0.5 pt |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Transversal |
||
| style="text-align:right" | 67 |
| style="text-align:right" | 67 |
||
| style="text-align:right" | +7% |
| style="text-align:right" | +7% |
||
| Line 1,403: | Line 1,276: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ NB CSM to NBV for |
|+ NB CSM to NBV for Life and Health. <sup>p. 14</sup> |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | Life |
! class="col-s" style="text-align:right" | Life |
||
| Line 1,430: | Line 1,303: | ||
|} |
|} |
||
</div> |
</div> |
||
* '''Health business''' written predominantly in Life entities is included <sup>p. 14</sup>. |
|||
* '''Changes''' are on a comparable basis (constant forex, scope, and methodology) <sup>p. 14</sup>. |
|||
* '''APPENDIX 9''': Other <sup>p. 15</sup>. |
|||
* '''APPENDIX 7''': Life & Health - Net Flows <sup>p. 15</sup>. |
|||
=== Net flows by business line === |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Life & Health net flows for 1Q25 and 1Q26. <sup>p. 15</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | 1Q25 |
! class="col-s" style="text-align:right" | 1Q25 |
||
| Line 1,453: | Line 1,319: | ||
| style="text-align:right" | +1.8 |
| style="text-align:right" | +1.8 |
||
|- |
|- |
||
| style="text-align:left" | G/A Savings |
| style="text-align:left" | G/A Savings {{footnote|1=General account.}} |
||
| style="text-align:right" | -0.7 |
| style="text-align:right" | -0.7 |
||
| style="text-align:right" | -0.8 |
| style="text-align:right" | -0.8 |
||
|- |
|- |
||
| style="text-align:left; padding-left:1.5em" | o/w capital light |
| style="text-align:left; padding-left:1.5em" | o/w capital light |
||
| style="text-align:right" | +0.6 |
| style="text-align:right" | +0.6 |
||
| style="text-align:right" | +0.7 |
| style="text-align:right" | +0.7 |
||
| Line 1,465: | Line 1,331: | ||
| style="text-align:right" | -1.5 |
| style="text-align:right" | -1.5 |
||
|- |
|- |
||
| style="text-align:left" | Unit-Linked |
| style="text-align:left" | Unit-Linked |
||
| style="text-align:right" | +0.5 |
| style="text-align:right" | +0.5 |
||
| style="text-align:right" | +0.7 |
| style="text-align:right" | +0.7 |
||
|- |
|- |
||
| style="text-align:left; font-weight:bold" | Total Life & Health |
| style="text-align:left; font-weight:bold" | Total Life & Health net flows |
||
| style="text-align:right; font-weight:bold" | +2.5 |
| style="text-align:right; font-weight:bold" | +2.5 |
||
| style="text-align:right; font-weight:bold" | +2.7 |
| style="text-align:right; font-weight:bold" | +2.7 |
||
|} |
|} |
||
</div> |
</div> |
||
* '''Health business''' written predominantly in Life entities is included <sup>p. 15</sup>. |
|||
* '''Capital light G/A''' encompasses all products with no guarantees, with guarantees at maturity only, or with guarantees equal to or lower than 0% <sup>p. 15</sup>. |
|||
* '''Investment contracts''' with no discretionary participation features ('DPF') are included <sup>p. 15</sup>. |
|||
* '''Main transactions in 2026''': AXA announced the execution of a share repurchase agreement for its share buyback program of up to EUR 1.25bn on February 27, 2026 <sup>p. 16</sup>. |
|||
* '''Next main investor events''': |
|||
** '''HY26 Earnings Release''' on July 31, 2026 <sup>p. 16</sup>. |
|||
** '''AXA Investor Day''' on September 15, 2026 <sup>p. 16</sup>. |
|||
** '''AXA Investor roundtable''' on the strategy for AXA key markets on September 21, 2026 <sup>p. 16</sup>. |
|||
** '''9M26 Activity Indicators''' on October 29, 2026 <sup>p. 16</sup>. |
|||
* '''APPENDIX 9''': Other <sup>p. 16</sup>. |
|||
* '''APPENDIX 8''': Main Transactions and Next Main Investor Events <sup>p. 16</sup>. |
|||
Revision as of 00:02, 18 June 2026
| Document info | |
|---|---|
| Organization | AXA |
| Year | 2026 |
| Period | 1Q |
| Period label | 1Q26 |
| Document type | Press release |
| Publication date | 2026-05-05 |
| Market timing | Pre-market |
| Language | English |
| Pages | 16 |
| Source | Original URL |
| Archive file | .md file |
This article summarizes AXA's 1Q 2026 activity indicators press release, published on 5 May 2026.
1Q26 highlights
- Gross written premiums & other revenues +6% to EUR 38.0bn vs. 1Q25 p. 1.
- Property & Casualty premiums +4% to EUR 21.5bn p. 1.
- Retail premiums +7%, with +4% from price effect and +3% from volumes p. 1.
- Commercial premiums +3%, with equal contributions from price effect and volumes p. 1.
- Life & Health premiums +8% to EUR 16.5bn p. 1.
- Life premiums +8% p. 1.
- Health premiums +8% p. 1.
- Property & Casualty premiums +4% to EUR 21.5bn p. 1.
- Life & Health NB CSM +4% p. 1.
- Net flows EUR +2.7bn p. 1.
- Solvency II ratio at 211% as of March 31, 2026, -4 points vs. January 1, 2026 (post-grandfathering period), reflecting resilience in a volatile environment p. 1.
Outlook 3
- AXA is on track to achieve underlying earnings per share growth for 2026 at the upper end of the 6-8% plan target range p. 1.
- AXA will present its new strategic plan for 2027-2029 on September 15, 2026 p. 1.
"AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy," said Alban de Mailly Nesle, Chief Financial Officer of AXA . "This performance underscores the continued robust expansion of our P&C businesses in both Retail and Commercial, with growth well balanced between pricing and volumes, while Life & Health revenues reflect the continuation of last year's strong momentum." p. 1
"In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan." p. 1
"I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA ." p. 1
- The press release was issued in Paris on May 5, 2026, at 5:45pm CET p. 1.
- All footnotes for this press release are on page 7 p. 1.
1Q26 key highlights
| Key figures (EUR billion) | 1Q25 | 1Q26 | Change | Change LFL |
|---|---|---|---|---|
| Gross written premiums and other revenues | 37.0 | 38.0 | +3% | +6% |
| o/w Property & Casualty (footnote: Natural catastrophe charges include natural catastrophe losses regardless of event size.) | 21.0 | 21.5 | +2% | +4% |
| o/w Life & Health (footnote: Combined ratio is a non-GAAP financial measure, or alternative performance measure (“APM”). Please see the paragraph “Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures” in this press release for important information about APMs used by AXA.) | 15.5 | 16.5 | +7% | +8% |
| o/w Asset Management (footnote: Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.) | 0.4 | n.m. | n.m. | n.m. |
| Key figures (EUR billion) | FY25 | January 1, 2026 | 1Q26 | Change vs. January 1, 2026 |
|---|---|---|---|---|
| Solvency II ratio (%) (footnote: The Solvency II ratio is estimated primarily using AXA’s internal model calibrated based on an adverse 1/200 years shock. It includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026, based on the full-year dividend of Euro 2.32 per share to be paid in 2026 for FY25 and annual share buyback of Euro 1.25 billion announced on February 26, 2026. Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stock- based compensation. Dividends and share buybacks are proposed by the Board, at its discretion based on a variety of factors described in AXA’s 2025 Universal Registration Document and then submitted to AXA’s shareholders for approval. This estimate should not be considered in any way to be an indication of the actual dividend and share buyback amounts, if any, for the 2026 financial year. For further information on AXA’s internal model and Solvency II disclosures, please refer to AXA Group’s Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on AXA’s website (www.axa.com).) | 224% | 215% | 211% | -4pts |
Activity indicators
- Total gross written premiums & other revenues +6% p. 2.
- Property & Casualty +4%, driven by:
- Personal lines +7%, due to higher volumes and favorable price effect p. 2.
- Commercial lines +3%, from higher volumes (notably at AXA XL Insurance) and favorable price effect, mainly in the SME & Mid-market business in Europe and France p. 2.
- AXA XL Reinsurance -7%, reflecting discipline in softening market conditions p. 2.
- Life & Health +8%, driven by:
- Life premiums +8%, due to strong sales in Unit-Linked (+16%) and G/A (+9%) across all geographies, and Protection (+4%) from strong sales in Protection with Savings in Hong Kong and Japan p. 2.
- Health premiums +8%, due to favorable price effects across all geographies p. 2.
- Property & Casualty +4%, driven by:
- Solvency II ratio was 211% as of March 31, 2026 p. 2.
- On January 1, 2026, the Solvency II ratio was 215% following the end of the grandfathering period (-10 points vs. December 31, 2025) p. 2.
- The Solvency II ratio was -4 points vs. January 1, 2026, reflecting:
- A strong operating return (+7 points) p. 2.
- Less accrued dividend and annual share buyback for 1Q26 (-6 points) p. 2.
- Unfavorable financial market movements (-4 points), notably from higher inflation expectations and elevated equity and interest rate volatility p. 2.
Property & Casualty
| Key figures (EUR billion) | 1Q25 | 1Q26 | Change LFL | 1Q26 Price effect 6 (in %) (footnote: Price effect is calculated as a percentage of total gross written premiums of the prior year.) |
|---|---|---|---|---|
| Gross written premiums and other revenues | 21.0 | 21.5 | +4% | +1.9% |
| o/w Commercial lines | 13.2 | 13.2 | +3% | +1.5% |
| o/w Personal lines | 6.4 | 7.0 | +7% | +4.0% |
| o/w AXA XL Reinsurance | 1.4 | 1.2 | -7% | -3.9% |
- Gross written premiums & other revenues +4% to EUR 21.5bn p. 3.
- Personal lines +7% to EUR 7.0bn, driven by:
- Europe (+7%), from favorable price effects across geographies (except UK & Ireland) and higher volumes p. 3.
- France (+8%), with strong volume growth from direct business and proprietary agent networks, combined with favorable price effect p. 3.
- Asia, Africa & EME LATAM (+7%), mainly driven by higher average premiums in Türkiye and higher volumes in Mexico p. 3.
- Commercial lines +3% to EUR 13.2bn, mainly from:
- AXA XL Insurance (+2%), from growth in Property and Specialty where margins remain attractive, partly offset by lower volumes in Casualty; pricing overall remains stable vs. 1Q25 p. 3.
- France (+6%), from both favorable price effect and higher volumes p. 3.
- Asia, Africa & EME-LATAM (+10%), mainly driven by higher average premiums in Türkiye p. 3.
- AXA XL Reinsurance -7% to EUR 1.2bn, reflecting lower volumes consistent with focus on maintaining profitability in a softer market environment, with pricing down -4% p. 3.
- Personal lines +7% to EUR 7.0bn, driven by:
- Group natural catastrophe experience in 1Q26 was slightly below the prorated annual budget p. 3.
- The annual natural catastrophe budget of approximately 4.5 points of combined ratio is maintained p. 3.
Life & Health
| Key figures (EUR billion) | 1Q25 | 1Q25 Updated* | 1Q26 | Change vs. 1Q25 updated LFL |
|---|---|---|---|---|
| Gross written premiums and other revenues | 15.5 | — | 16.5 | +8% |
| o/w Life | 9.8 | — | 10.5 | +8% |
| o/w Health | 5.6 | — | 5.9 | +8% |
| PVEP | 13.7 | 13.0 | 13.8 | +8% |
| NB CSM (pre-tax) | 0.6 | 0.6 | 0.6 | +4% |
| NBV (post-tax) | 0.7 | 0.6 | 0.6 | +1% |
| NBV margin | 4.9% | 4.8% | 4.4% | -0.3pt |
| Net flows | +2.5 | — | +2.7 | — |
- 1Q25 PVEP, NB CSM, NBV, and NBV margin have been updated based on FY25 financial and actuarial assumptions for comparability, reflecting their contribution to FY25 PVEP, NB CSM, NBV, and NBV margin p. 4.
- All year-on-year changes are on a comparable basis vs. the updated 1Q25 figures p. 4.
- Gross written premiums & other revenues +8% to EUR 16.5bn p. 4.
- Life premiums +8% to EUR 10.5bn, driven by:
- Unit-Linked (+16%), from continued positive sales momentum across geographies p. 4.
- G/A Savings (+9%), mainly from successful commercial campaigns in Spain, strong single-premium sales in Japan, good performance of G/A capital-light products in Italy, and positive momentum in Individual Savings in Switzerland p. 4.
- Protection (+4%), primarily from continued success of Protection with G/A savings in Hong-Kong and Protection with Unit-Linked in Japan, as well as Individual Protection with Savings in Switzerland p. 4.
- Health premiums +8% to EUR 5.9bn, driven by favorable price effects across all geographies p. 4.
- Life premiums +8% to EUR 10.5bn, driven by:
- PVEP +8% to EUR 13.8bn, driven by:
- Life (+10%), reflecting strong sales across geographies in both Savings (+14%) and Protection (+6%), partly offset by lower Group Life sales in Switzerland p. 4.
- Health (+4%), mainly due to higher Group business volumes in France, partly offset by Japan p. 4.
- NB CSM (pre-tax) +4% to EUR 0.6bn, driven by strong Savings and Protection sales across most geographies, partly offset by unfavorable mix, including lower Group Life sales in Switzerland and Health sales in Japan p. 4.
- NBV (post-tax) +1% to EUR 0.6bn, as NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China p. 4.
- NBV margin -0.3 points to 4.4% p. 4.
- Net flows EUR +2.7bn (vs. EUR +2.5bn in 1Q25), driven by:
- Protection (EUR +1.8bn), mainly in Hong Kong and Switzerland in Individual Life, and in Japan in Protection with Unit-Linked product p. 4.
- Unit-Linked (EUR +0.7bn), primarily in France p. 4.
- G/A Savings (EUR -0.8bn), reflecting inflows in capital-light G/A savings (EUR +0.7bn), more than offset by outflows in traditional G/A Savings (EUR -1.5bn) p. 4.
- Health (EUR +1.0bn), mostly from Germany, France and Japan p. 4.
Ratings
| Insurer financial strength ratings | AXA's credit ratings (footnote: Restricted Tier 1: “A-” by Standard & Poor’s and “A3(hyb)” by Moody’s. Tier 2: “A” by Standard & Poor’s and “A1(hyb)” by Moody’s.) | |||||
|---|---|---|---|---|---|---|
| Agency | Date of last review | AXA SA | AXA's principal insurance subsidiaries | Outlook | Senior debt of the Company | Short-term debt of the Company |
| S&P Global Ratings | March 11, 2026 | AA- | AA | Stable | AA- | A-1+ |
| Moody's Investor Service | October 8, 2025 | Aa2 | Aa2 | Stable | Aa3 | P-1 |
| AM Best | October 9, 2025 | A+ Superior | — | Stable | aa Superior | — |
Glossary
- Capital-light G/A products encompass all products with no guarantees, with guarantees at maturity only, or with guarantees equal to or lower than 0% p. 5.
- Contractual service margin ('CSM') is a component of the carrying amount of the asset or liability for a group of insurance contracts, representing the unearned profit to be recognized as services are provided to policyholders p. 5.
- Gross written premiums and other revenues are insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business) p. 5.
- Other Revenues represent premiums and fees collected on activities other than insurance (i.e., banking, services, and asset management activities) p. 5.
- New business contractual service margin ('NB CSM') is a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided p. 5.
- New business value ('NBV') is the value of newly issued contracts during the current year, consisting of:
- The NB CSM p. 5.
- The present value of future profits of Short-Term Business newly issued contracts during the period, carried by Life entities, considering expected renewals p. 5.
- The present value of future profits of pure investment contracts accounted for under IFRS 9 p. 5.
- Net of the cost of reinsurance, taxes, and minority interests p. 5.
- New business value margin ('NBV Margin') is the ratio of NBV to PVEP p. 5.
- Present value of expected premiums ('PVEP') is the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term, discounted at the reference interest rate and representing the Group share p. 5.
- AA: Senior Debt Rating
- AM: AM Best
- BNP: Banque Nationale de Paris
- CLP: Credit and Lifestyle Protection
- CSM: Contractual Service Margin
- EME LATAM: Emerging Markets Europe Latin America
- EME: Emerging Markets Europe
- IFRS: International Financial Reporting Standards
- II: Solvency II
- LATAM: Latin America
- LFL: Like-for-Like
- NB CSM: New Business Contractual Service Margin
- NBV: New Business Value
- PVEP: Present Value of Expected Premiums
- SME: Small and Medium-sized Enterprises
- UK: United Kingdom
Scope
- France includes insurance activities, banking activities, and holding p. 6.
- Europe includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxembourg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holding), Italy (insurance activities), Prima (insurance activities), AXA Health International (insurance activities), and AXA Life Europe (insurance activities) p. 6.
- AXA XL includes insurance and reinsurance activities and holding p. 6.
- Asia, Africa & EME-LATAM includes:
- Asia: Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, Indonesia L&S (excluding the bancassurance entity), China P&C, South Korea, and Asia Holdings (fully consolidated); China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S (the bancassurance entity) (consolidated under the equity method, contributing only to NBV, PVEP, underlying earnings, and net income) p. 6.
- Africa: Egypt (insurance activities and holding), Morocco (insurance activities and holding), and Nigeria (insurance activities and holding) (fully consolidated) p. 6.
- EME-LATAM: Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding) (fully consolidated); Russia (Reso) (insurance activities) (consolidated under the equity method, contributing only to net income) p. 6.
- AXA Mediterranean Holdings p. 6.
- Transversal & Other includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA (including the Group's internal reinsurance activity), and other Central Holdings p. 6.
- The disposal of AXA Investment Managers to BNP Paribas was completed on July 1, 2025 p. 6.
Exchange rates
| — | FY25 | 1Q26 | 1Q25 | 1Q26 |
|---|---|---|---|---|
| USD | 1.17 | 1.15 | 1.05 | 1.17 |
| CHF | 0.93 | 0.93 | 0.95 | 0.92 |
| GBP | 0.87 | 0.87 | 0.84 | 0.87 |
| JPY | 184 | 183 | 160 | 184 |
| HKD | 9.14 | 9.03 | 8.19 | 9.14 |
Notes
- Changes in gross written premiums & other revenues, new business value (NBV), present value of expected premiums (PVEP), and new business value margin (NBV Margin) are on a comparable basis (constant forex, scope, and methodology) unless otherwise indicated p. 7.
- These and other terms are defined in the glossary section of the press release p. 7.
- The Solvency II ratio is estimated using AXA's internal model, calibrated based on an adverse 1/200 years shock p. 7.
-
| — | 1Q25 Published | 1Q25 Adjusted ii,iii | 1Q26 | Change | Change LFL | 1Q26 | Change LFL | 1Q26 | Change LFL |
|---|---|---|---|---|---|---|---|---|---|
| France | 8,440 | 7,923 | 8,393 | +6% | +5% | 3,355 | +6% | 5,012 | +4% |
| Europe | 15,289 | 15,608 | 16,905 | +8% | +6% | 9,328 | +4% | 7,577 | +9% |
| AXA XL | 6,984 | 6,984 | 6,488 | -7% | 0% | 6,459 | 0% | 29 | -1% |
| Asia, Africa & EME-LATAM | 5,286 | 5,286 | 5,403 | +2% | +11% | 1,719 | +8% | 3,684 | +13% |
| Transversal | 525 | 723 | 764 | +6% | +6% | 601 | +8% | 163 | -2% |
| AXA Investment Managers | 443 | 443 | - | n.m. | n.m. | — | — | — | — |
| Total | 36,967 | 36,967 | 37,953 | +3% | +6% | 21,462 | +4% | 16,464 | +8% |
| — | Total Commercial | Change | Personal Motor | Change | Personal Non-Motor | Change | Total Personal | Change | Total Reinsurance | Change | 1Q26 | Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France | 2,061 | +6% | 766 | +10% | 528 | +4% | 1,294 | +8% | — | — | 3,355 | +6% |
| Europe | 4,388 | +1% | 3,370 | +10% | 1,570 | +2% | 4,940 | +7% | — | — | 9,328 | +4% |
| AXA XL | 5,215 | +2% | — | — | — | — | — | — | 1,244 | -7% | 6,459 | 0% |
| Asia, Africa & EME-LATAM | 952 | +10% | 577 | +8% | 190 | +2% | 767 | +7% | — | — | 1,719 | +8% |
| Transversal | 601 | +8% | — | — | — | — | — | — | — | — | 601 | +8% |
| Total | 13,217 | +3% | 4,712 | +9% | 2,288 | +2% | 7,001 | +7% | 1,244 | -7% | 21,462 | +4% |
Interest rates (5Y) for the discounting of P&C claims reserves
| — | FY25 i | 1Q26 ii |
|---|---|---|
| EUR | 2.6% | 2.7% |
| USD | 4.2% | 4.0% |
| JPY | 1.0% | 1.6% |
| GBP | 4.3% | 4.2% |
| CHF | 0.2% | 0.2% |
| HKD | 3.2% | 2.8% |
| 1Q26 (in %) | Commercial lines | Personal lines | AXA XL Reinsurance |
|---|---|---|---|
| France | +3.5% | +2.6% | — |
| Europe | +3.0% | +4.2% | — |
| Switzerland | +4.0% | +5.1% | — |
| Germany | +2.5% | +4.2% | — |
| Belgium & Luxembourg | +2.2% | +2.4% | — |
| UK & Ireland | +0.5% | -0.9% | — |
| Spain | +5.7% | +6.0% | — |
| Italy | +2.7% | +3.8% | — |
| AXA XL | -0.2% | — | -3.9% |
| Asia, Africa & EME-LATAM | +0.4% | +5.6% | — |
| Total | +1.5% | +4.0% | -3.9% |
| — | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change |
|---|---|---|---|---|---|---|---|---|---|---|
| France | 5,012 | +4% | 996 | +3% | 1,325 | +1% | 1,437 | +7% | 1,253 | +4% |
| Europe | 7,577 | +9% | 1,986 | 0% | 1,263 | +16% | 1,044 | +24% | 3,283 | +8% |
| AXA XL | 29 | -1% | 15 | +1% | 14 | -2% | — | — | — | — |
| Asia, Africa & EME-LATAM | 3,684 | +13% | 1,764 | +10% | 319 | +27% | 224 | +35% | 1,377 | +10% |
| Transversal | 163 | -2% | 132 | -1% | — | — | — | — | 31 | -5% |
| Total | 16,464 | +8% | 4,893 | +4% | 2,922 | +9% | 2,705 | +16% | 5,944 | +8% |
| o/w short-term | 5,436 | +6% | 1,183 | +1% | — | — | — | — | 4,253 | +7% |
| — | Life | Healthⁱ | Totalⁱ | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France | 3,026 | 94 | 103 | 3.4% | 1,565 | — | 44 | 2.8% | 4,591 | 94 | 147 | 3.2% |
| Europe | 2,982 | 183 | 161 | 5.4% | 1,627 | 74 | 66 | 4.0% | 4,609 | 257 | 227 | 4.9% |
| Asia, Africa & EME-LATAM | 3,128 | 178 | 185 | 5.9% | 612 | 67 | 61 | 9.9% | 3,740 | 245 | 246 | 6.6% |
| Transversal | 63 | 5 | 3 | 5.2% | — | — | — | — | 63 | 5 | 3 | 5.2% |
| Total | 9,199 | 460 | 452 | 4.9% | 3,805 | 141 | 170 | 4.5% | 13,003 | 601 | 623 | 4.8% |
| — | Life | Healthᶦ | Totalᶦ | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France | 6,969 | 204 | 245 | 3.5% | 3,261 | — | 82 | 2.5% | 10,229 | 204 | 327 | 3.2% |
| Europe | 5,585 | 328 | 271 | 4.8% | 2,109 | 83 | 76 | 3.6% | 7,694 | 410 | 347 | 4.5% |
| Asia, Africa & EME-LATAM | 6,228 | 389 | 380 | 6.1% | 1,120 | 140 | 120 | 10.7% | 7,347 | 529 | 500 | 6.8% |
| Transversal | 153 | 12 | 8 | 5.2% | — | — | — | — | 153 | 12 | 8 | 5.2% |
| Total | 18,934 | 934 | 904 | 4.8% | 6,490 | 223 | 278 | 4.3% | 25,424 | 1,156 | 1,182 | 4.6% |
| — | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) | PVEP | NB CSM (pre-tax) | NBV (post-tax) | NBV margin (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France | 9,911 | 277 | 344 | 3.5% | 4,788 | — | 116 | 2.4% | 14,698 | 277 | 459 | 3.1% |
| Europe | 7,900 | 450 | 365 | 4.6% | 3,215 | 114 | 104 | 3.2% | 11,115 | 564 | 469 | 4.2% |
| Asia, Africa & EME-LATAM | 9,408 | 600 | 592 | 6.3% | 1,502 | 199 | 167 | 11.1% | 10,910 | 799 | 759 | 7.0% |
| Transversal | 230 | 18 | 12 | 5.2% | — | — | — | — | 230 | 18 | 12 | 5.2% |
| Total | 27,448 | 1,345 | 1,312 | 4.8% | 9,505 | 313 | 387 | 4.1% | 36,953 | 1,659 | 1,698 | 4.6% |
| EUR million | Life | Healthⁱ | Totalⁱ |
|---|---|---|---|
| NB CSM (pre-tax) | 460 | 141 | 601 |
| Other NBV (pre-tax) | 133 | 82 | 215 |
| Tax | -141 | -53 | -194 |
| Total NBV | 452 | 170 | 623 |
| EUR million | Life | Health i | Total i |
|---|---|---|---|
| NB CSM (pre-tax) | 934 | 223 | 1,156 |
| Other NBV (pre-tax) | 258 | 144 | 402 |
| Tax | -288 | -89 | -377 |
| Total NBV | 904 | 278 | 1,182 |
| EUR million | Life | Health i | Total i |
|---|---|---|---|
| NB CSM (pre-tax) | 1,345 | 313 | 1,659 |
| Other NBV (pre-tax) | 384 | 198 | 583 |
| Tax | -418 | -125 | -543 |
| Total NBV | 1,312 | 387 | 1,698 |
| — | PVEP | Change | NB CSM (pre-tax) | Change | NBV (post-tax) | Change | NBV margin (%) | Change | PVEP | Change | NB CSM (pre-tax) | Change | NBV (post-tax) | Change | NBV margin (%) | Change | PVEP | Change | NB CSM (pre-tax) | Change | NBV (post-tax) | Change | NBV margin (%) | Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France | 3,348 | +11% | 96 | +2% | 112 | +8% | 3.3% | -0.1 pt | 1,815 | +16% | — | — | 46 | +5% | 2.5% | -0.3 pt | 5,162 | +12% | 96 | +2% | 158 | +7% | 3.1% | -0.1 pt |
| Europe | 3,287 | +8% | 187 | -1% | 156 | -5% | 4.8% | -0.7 pt | 1,707 | +4% | 89 | +17% | 77 | +15% | 4.5% | +0.4 pt | 4,994 | +7% | 275 | +4% | 233 | 0% | 4.7% | -0.3 pt |
| Asia, Africa & EME-LATAM | 3,129 | +11% | 178 | +13% | 178 | +7% | 5.7% | -0.2 pt | 407 | -26% | 46 | -22% | 37 | -32% | 9.1% | -0.8 pt | 3,536 | +5% | 224 | +4% | 215 | -2% | 6.1% | -0.5 pt |
| Transversal | 67 | +7% | 5 | +7% | 3 | +7% | 5.2% | 0.0 pt | — | — | — | — | — | — | — | — | 67 | +7% | 5 | +7% | 3 | +7% | 5.2% | 0.0 pt |
| Total | 9,831 | +10% | 466 | +5% | 450 | +3% | 4.6% | -0.3 pt | 3,929 | +4% | 135 | -1% | 160 | -4% | 4.1% | -0.4 pt | 13,760 | +8% | 601 | +4% | 609 | +1% | 4.4% | -0.3 pt |
| EUR million | Life | Health i | Total i |
|---|---|---|---|
| NB CSM (pre-tax) | 466 | 135 | 601 |
| Other NBV (pre-tax) | 125 | 73 | 198 |
| Tax | -142 | -48 | -190 |
| NBV | 450 | 160 | 609 |
| EUR billion | 1Q25 | 1Q26 |
|---|---|---|
| Health i | +0.8 | +1.0 |
| Protection | +1.8 | +1.8 |
| G/A Savings (footnote: General account.) | -0.7 | -0.8 |
| o/w capital light | +0.6 | +0.7 |
| o/w traditional G/A | -1.3 | -1.5 |
| Unit-Linked | +0.5 | +0.7 |
| Total Life & Health net flows | +2.5 | +2.7 |